Kantonsspital St.Gallen

Interferon-γ Release Assay (IGRA) Negativity Rates after TB-Treatment in HIV-infected Individuals

Morten Ruhwald, Barbara Hasse, Lukas Fenner & Patrick Schmid


Interferon-γ Release assays (IGRA) have partly replaced conventional tuberculin skin tests (TST) in the recent years due to their higher specificity and standardised test procedures including a positive / negative control. Nevertheless it is currently unknown if IGRA reverse to negative results and in what time after successful TB-treatment in HIV-infected persons.

Study Aims:
The aim of the study is to evaluate the rate of positive / negative / indeterminate IGRA test results and absolute Mycobacterium tuberculosis-specific cytokine / chemokine secretion (IGRA-specific and purified protein derivate (PPD) –specific) titres in association with the time since successful tuberculosis (TB) -treatment as an indicator of the IGRA reversion rate over time, taking into account possible confounders, in particular CD4 recovery rate and TB re-exposure risk.

Study Design:
Cohort study analysing the effect of time since TB-treatment on IGRA / PPD negativity rates in all HIV-infected patients enrolled in the SHCS with previous treatment for active TB.
project partner Swiss HIV Cohort Study (SHCS)
type of project clinical studies
status automatically closed
start of project 2012
end of project 2013
responsible person Matthias Hoffmann, MD